Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine

Lancet

Volumn 351, Issue 9115, 1998, Pages 1547-1551

  Foudraine, Norbert A ^a,c   Hoetelmans, Richard M W ^b   Lange, Joep M A ^c   De Wolf, Frank ^c   Van Benthem, Birgit H B ^a   Maas, Jaap J ^a   Keet, Ireneus P M ^a   Portegies, Peter ^c  

^a MUNICIPAL HEALTH SERVICE   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR PUNCTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032560373     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07333-4     Document Type: Article

References (31)

1. 1 Goudsmit J, de Wolf F, Paul DA, et al. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986; ii: 177-80.
2. 2 Davis LE, Hjelle BL, Miller VE, et al. Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 1992; 42: 1736-39.
3. 3 Ho DD, Sarngadharan MG, Resnick L, et al. Primary human T-lymphotropic virus type III infection. Ann Intern Med 1985; 103: 880-83.
4. 4 Portegies P, Enting RH, de Gand J, et al. Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, the Netherlands. AIDS 1993; 7: 669-75.
5. 5 Bacellar H, Munoz A, Miller EN, et al. Temporal Trends in the incidence of HIV-1 related neurological disease: multicenter AIDS cohort study, 1985-1992. Neurology 1994; 44: 1892-900.
6. 6 Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 39-44.
7. 7 Lupia RH, Ferencz N, Lertora JJL, et al. Comparative pharmacokinetics of the prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. Antimicrob Agents Chemother 1993; 37: 818-24.
8. 8 Gisslén M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis 1997; 175: 434-47.
9. 9 Sei S, Stewart SK, Parley M, et al. Evaluation of human immunodeficiency virus (HIV) type 1 RNA levels in cerebrospinal fluid and viral resistance to zidovudine in children with HIV encephalopathy. J Infect Dis 1996; 174: 1200-06.
10. 10 Dudley MN, Graham KK, Kaul S, et al. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis 1992; 166: 480-85.
11. 11 Lewis LL, Venzon D, Church J, et al. Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1996; 174: 16-25.
12. 12 Kline MW, Dunkle LM, Church JA, et al. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics 1995; 96: 247-52.
13. 13 Power C, Seines OA, Grim JA, McArthur JC. HIV dementia scale: a rapid screening test. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 273-78.
14. 14 Burger DM, Meenhorst PL, Bult A, Beijnen JH. Evaluation of two immunoassays for the determination of zidovudine in biological matrices. J Drug Dev Clin Pract 1996; 7: 313-18.
15. 15 Harker AJ, Evans GL, Hawley AE, Morris DM. High-performance liquid Chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J Chromatogr B Biomed Sci Appl 1994; 657: 227-32.
16. 16 Burger DM, Rosing H, van Gijn R, Meenhorst PL, van Tellingen O, Beijnen JH. Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1992; 584: 239-47.
17. 17 Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virological response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDZ) versus ZDV plus 3TC in previously untreated patients. AIDS 1996; 10: 975-81.
18. 18 Lea AP, Faulds D. Stavudine. A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51: 846-64.
19. 19 Jellinger RM, Shafer RW, Merigan TC. A novel approach to assessing the drug susceptibility and replication of human immundeficiency virus type 1 isolates. J Infect Dis 1997; 175: 561-66.
20. 20 Hitchcock MJM. 2′, 3′,-didehydro-2′, 3′,-dideoxythymidine (d4T), an anti HIV agent. Antiviral Chem Chemother 1991; 2: 125-32.
21. 21 Lakeman FD, Whitley RD. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain biopsied patients and correlation with disease. J Infect Dis 1995; 171: 857-63.
22. 22 Cinque P, Vago L, Brytting M, et al. Cytomegalovirus infection of the central nervous system in patients with AIDS: diagnosis by DNA amplification from cerebrospinal fluid. J Infect Dis 1992; 166: 1408-11.
23. 23 Jeffrey KJM, Read SJ, Peto TEA, Mayon-White RT, Bangham CRM. Diagnosis of viral infections of the central nervous system: clinical interpretation of PCR results. Lancet 1997; 349: 313-17.
24. 24 Brew BJ, Bhalla RB, Paul M , et al. Cerebrospinal fluid B2-microglobulin in patients with AIDS dementia complex: an expanded series including response to zidovudine treatment. AIDS 1992; 6: 461-65.
25. 25 Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol 1990; 28: 556-60.
26. 26 Portegies P, Epstein LG, Hung ST, de Gans J, Goudsmit J. Human immunodeficiency virus type 1 antigen in cerebrospinal fluid. Arch Neurol 1989; 46: 261-64.
27. 27 Royal W, Selnes OA, Concha M, Nance-Sproson TE, McArthur JC. Cerebrospinal fluid human immunodeficiency type 1 (HIV-1) p24 antigen levels in HIV-1-related dementia. Ann Neurol 1994; 36: 32-39.
28. 28 Burger DM, Kraaijeveld CL, Meenhorst PL, et al. Penetration of zidovudine into the cerebrospinal fluid of patients infected with HIV. AIDS 1993; 7: 1581-87.
29. 29 Hagberg L, Andersson M, Chiodi F, et al. Effect of zidovudine on cerebrospinal fluid in patients with HIV infection and acute neurological disease. Scan J Infect Dis 1991; 23: 681-85.
30. 30 Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407-12.
31. 31 Brew BJ, Dunbar N, Druett J, Freund J, Ward P. Pilot study of the efficacy of atevirdine in the treatment of AIDS dementia complex. AIDS 1996; 10: 1357-60.